Health News Archive - November 16, 2005
Vietnamese scientists have found more variations of bird flu viruses in poultry, adding to the health risk to people if these strains keep circulating, a health official said on Wednesday.
By Moorman, Jonathan; Saad, Mustafa; Kosseifi, Semaan; Krishnaswamy, Guha Hepatitis C virus (HCV) infection is a chronic blood-borne disease that affects > 4,000,000 individuals in the United States.
By Duwe, Beau V; Sterman, Daniel H; Musani, Ali I Tumors of the mediastinum represent a wide diversity of disease states. The location and composition of a mass is critical to narrowing the differential diagnosis.
By Young, David W "What's the use of running if you are not on the right road?" So says a German proverb, and it's a question that healthcare organizations should be asking themselves.
By Masi, Mar; Gutirrez, Flix; Shum, Conrado; Padilla, Sergio; Et al Study objectives: To evaluate the usefulness of procalcitonin serum levels as a predictor of etiology and prognosis in adult patients with community-acquired pneumonia (CAP) when they are stratified according to severity.
Mouth cancer linked to smoking and drinking now kills more people in the UK than cervical and testicular cancer together, experts said on Wednesday.
By Alan Elsner WASHINGTON (Reuters) - Sixty years after the opening of the Nuremberg trials of top Nazis following the Second World War, the tribunal's legacy reverberates loudly in international human rights law and in the trial of former Iraqi President Saddam Hussein.
LONDON (Reuters) - GlaxoSmithKline Plc said on Wednesday clinical results confirmed the benefits of its CDA treatment for drug-resistant malaria and that it was planning final Phase III trials to confirm its safety and efficacy.
DALLAS (Reuters) - Abbott Laboratories Inc.'s experimental heart failure drug Simdax failed to significantly improve survival over the current standard treatment for the sickest patients after 180 days, according to a new study presented on Wednesday.
DALLAS (Reuters) - A diabetes drug sold by Takeda Pharmaceutical Co. and Eli Lilly and Co. significantly cut the rate of a second heart attack compared with a placebo in high-risk patients with type-2 diabetes, a study reported on Wednesday found.